www.fdanews.com/articles/195782-aimmune-therapeutics-nabs-first-peanut-allergy-treatment-approval
Aimmune Therapeutics Nabs First Peanut Allergy Treatment Approval
February 6, 2020
Aimmune Therapeutics received the FDA’s approval for Palforzia (peanut allergen powder-dnfp) to mitigate allergic reactions, including anaphylaxis, that may occur from accidental exposure to peanut in patients with confirmed peanut allergy.
Given breakthrough therapy designation in 2015, Palforzia is the first approved treatment for patients with peanut allergy.
The Allergenic Products Advisory Committee voted in favor of the risk-benefit profile of the oral immunotherapy in September 2019.